Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger…
Month: February 2021
Red Light Holland Announces Increase in Bought Deal Equity Financing to $10 Million
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED…
Medexus Announces Upsize to Previously Announced Bought Deal Public Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED…
Yield10 Bioscience Announces Closing of $12.7 Million Public Offering
WOBURN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural…
Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021 at 9:00 AM
The access information for the investor conference call is as follows: Domestic US/Canada – 1-(866)…
Alliance for Regenerative Medicine Responds to EU Beating Cancer Plan
Alliance for Regenerative Medicine Responds to EU Beating Cancer Plan ATMPs are uniquely positioned to…
Skye Bioscience to Participate in Investment Conferences in February
San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE”…
Telo Genomics Retains Former Abbott & Siemens Veteran Gregg Mayer to Lead the Development of the Company’s Industry Partnership Strategy
TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) — Telo Genomics Corp. (TSX-V: TELO) (the “Company” or…
PDS Biotech Announces Preliminary Efficacy Achievement in Phase 2 Combination Trial of PDS0101 Led by the National Cancer Institute
Full enrollment triggered by observation of 3 objective responses in continued evaluation of the initial…
AXIM® Biotechnologies Begins Clinical Trials on Its ImmunoPass Rapid Diagnostic Test With Vaccine Recipients
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,”…
Marrone Bio Innovations Issues Shareholder Letter
DAVIS, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) — Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone…
UPDATE – CytomX Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage,…
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Study reached primary and secondary endpoints of safety and immunogenicity, respectively VXA-CoV2-1 induced potent CD8+…
Enzo Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin
NEW YORK, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or…
electroCore to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
ROCKAWAY, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine…
Aligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS),…
Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO)…
Mydecine Innovations Group Appoints Josephine Wu to Board of Directors
Provides update on U.S. OTC Listing DENVER, Feb. 03, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations…
Strongbridge Biopharma plc Announces New Employment Inducement Awards
DUBLIN, Ireland and TREVOSE, Pa., Feb. 03, 2021 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq:…
Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update
Phase II (16 patients treated, 9/16 (56%) with severe illness, 7/16 (44%) with critical illness,…